EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Finerenone in Diabetic Kidney Disease

Adam Cohn

Canadian Diabetes & Endocrinology Today · 2024

DOI: 10.58931/cdet.2024.2229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Diabetes & Endocrinology Today, 2024. Verfasst von Adam Cohn. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) affects 40% of individuals with diabetes mellitus (T2DM) and is associated with an increased risk of cardiovascular events, hospitalization for heart failure, and premature death. Existing treatments focus on lifestyle measures, glycemic control, blood pressure and lipid management, inhibition of the renin‑angiotensin‑aldosterone system (RAAS), and the use of sodium glucose cotransporter 2 inhibitors (SGLT2-i). However, substantial residual risk of progression to end-stage kidney disease (ESKD) or cardiovascular complications remain despite optimal therapy. Finerenone, a non-steroidal mineralocorticoid antagonist (MRA), has been shown to reduce important outcomes when added to evidence-based therapies, and is approved by Health Canada as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and T2DM to reduce the risk of ESKD and a sustained decrease in estimated glomerular filtration rate (eGFR), cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure.

Zitieren

APA

Cohn, A. (2024). Finerenone in Diabetic Kidney Disease. Canadian Diabetes & Endocrinology Today. https://doi.org/10.58931/cdet.2024.2229

Vancouver

Cohn A. Finerenone in Diabetic Kidney Disease. Canadian Diabetes & Endocrinology Today. 2024. doi:10.58931/cdet.2024.2229

BibTeX
@article{Cohn2024,
  author = {Cohn, Adam},
  title = {Finerenone in Diabetic Kidney Disease},
  journal = {Canadian Diabetes & Endocrinology Today},
  year = {2024},
  doi = {10.58931/cdet.2024.2229}
}
Kostenlos starten →